Search research articles
Contact Us
Filters
Showing results (401-410 of 823) with videos related to
Page
of 83
Sort By:
Oncogene
|
September 24, 2013
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer
R Nair, D L Roden, W S Teo, et al.
Blood
|
February 26, 2025
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
Yanmin M Zhao, Yi Luo, Jimin M Shi, et al.
European Journal of Neurology
|
February 6, 2014
Cortical thickness and hippocampal shape in pure vascular mild cognitive impairment and dementia of subcortical type
H J Kim, B S Ye, C W Yoon, et al.
Molecular Cancer Therapeutics
|
April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models
Tinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Cancer Cell
|
December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Nature Medicine
|
April 21, 2015
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.
Cancer Discovery
|
May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A Wander, Ofir Cohen, Xueqian Gong, et al.
Journal of Medicinal Chemistry
|
January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Cancer Discovery
|
October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene
Xueqian Gong, Jian Du, Stephen H Parsons, et al.
Page
of 83
Search research articles
Search
Showing results (401-410 of 823) with videos related to
Sort By:
Page
of 83
Oncogene
|
September 24, 2013
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer
R Nair, D L Roden, W S Teo, et al.
Blood
|
February 26, 2025
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
Yanmin M Zhao, Yi Luo, Jimin M Shi, et al.
European Journal of Neurology
|
February 6, 2014
Cortical thickness and hippocampal shape in pure vascular mild cognitive impairment and dementia of subcortical type
H J Kim, B S Ye, C W Yoon, et al.
Molecular Cancer Therapeutics
|
April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models
Tinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Cancer Cell
|
December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Nature Medicine
|
April 21, 2015
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.
Cancer Discovery
|
May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A Wander, Ofir Cohen, Xueqian Gong, et al.
Journal of Medicinal Chemistry
|
January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Cancer Discovery
|
October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene
Xueqian Gong, Jian Du, Stephen H Parsons, et al.
Page
of 83